Terms: = Thyroid cancer AND VHL, HRCA1, P40337, 7428, ENSG00000134086, RCA1, VHL1
70 results:
1. Clinico-pathologic profile and outcomes of pediatric endocrine patients managed by endocrine surgeons: Experience over three decades in a tertiary center in India.
Vikram S; Mishra A; Bhatia V; Mayilvagnan S; Chand G; Agarwal G; Agarwal A; Dabadghao P; Mishra SK
World J Surg; 2024 Mar; 48(3):729-738. PubMed ID: 38299448
[TBL] [Abstract] [Full Text] [Related]
2. Personalized Systemic Therapies in Hereditary cancer Syndromes.
Mastrodomenico L; Piombino C; Riccò B; Barbieri E; Venturelli M; Piacentini F; Dominici M; Cortesi L; Toss A
Genes (Basel); 2023 Mar; 14(3):. PubMed ID: 36980956
[TBL] [Abstract] [Full Text] [Related]
3. Identifying metastatic renal cell carcinoma in thyroid fine-needle aspirates by molecular testing.
Freeman T; Taneja C; Ohori NP; Wald AI; Skaugen J; Yip L; Kim S; Ferris RL; Nikiforova MN; Roy S; Nikiforov YE
Endocr Relat Cancer; 2022 Dec; 29(12):657-664. PubMed ID: 36205930
[TBL] [Abstract] [Full Text] [Related]
4. vhl tumor suppressor as a novel potential candidate biomarker in papillary thyroid carcinoma.
Todorović L; Stanojević B
Biomol Biomed; 2023 Feb; 23(1):26-36. PubMed ID: 36036061
[TBL] [Abstract] [Full Text] [Related]
5. Observational study of population genomic screening for variants associated with endocrine tumor syndromes in a large, healthcare-based cohort.
Savatt JM; Ortiz NM; Thone GM; McDonald WS; Kelly MA; Berry ASF; Alvi MM; Hallquist MLG; Malinowski J; Purdy NC; Williams MS; Sturm AC; Buchanan AH
BMC Med; 2022 Jun; 20(1):205. PubMed ID: 35668420
[TBL] [Abstract] [Full Text] [Related]
6. Clinicopathological and Molecular Features of Secondary cancer (Metastasis) to the thyroid and Advances in Management.
Nguyen M; He G; Lam AK
Int J Mol Sci; 2022 Mar; 23(6):. PubMed ID: 35328664
[TBL] [Abstract] [Full Text] [Related]
7. [Endocrine and neuroendocrine tumors].
Riss P; Scheuba K; Strobel O
Chirurg; 2021 Nov; 92(11):996-1002. PubMed ID: 34618164
[TBL] [Abstract] [Full Text] [Related]
8. The Association of the BRAF-V600E Mutation with the Expression of the Molecular Markers in the Primary Tumor and Metastatic Tissue in Papillary thyroid cancer.
Spirina LV; Chizhevskaya SY; Kovaleva IV; Kondakova IV
Asian Pac J Cancer Prev; 2021 Jul; 22(7):2017-2024. PubMed ID: 34319022
[TBL] [Abstract] [Full Text] [Related]
9. Phakomatoses and Endocrine Gland Tumors: Noteworthy and (Not so) Rare Associations.
Chevalier B; Dupuis H; Jannin A; Lemaitre M; Do Cao C; Cardot-Bauters C; Espiard S; Vantyghem MC
Front Endocrinol (Lausanne); 2021; 12():678869. PubMed ID: 34025587
[TBL] [Abstract] [Full Text] [Related]
10. Genetic Analysis and Clinical Characteristics of Hereditary Pheochromocytoma and Paraganglioma Syndrome in Korean Population.
Choi H; Kim KJ; Hong N; Shin S; Choi JR; Kang SW; Lee ST; Rhee Y
Endocrinol Metab (Seoul); 2020 Dec; 35(4):858-872. PubMed ID: 33397040
[TBL] [Abstract] [Full Text] [Related]
11. Clinicopathologic features of kinase fusion-related thyroid carcinomas: an integrative analysis with molecular characterization.
Chu YH; Wirth LJ; Farahani AA; Nosé V; Faquin WC; Dias-Santagata D; Sadow PM
Mod Pathol; 2020 Dec; 33(12):2458-2472. PubMed ID: 32737449
[TBL] [Abstract] [Full Text] [Related]
12. Screening guidelines and recommendations for patients at high risk of developing endocrine cancers.
Geurts JL; Strong EA; Wang TS; Evans DB; Clarke CN
J Surg Oncol; 2020 May; 121(6):975-983. PubMed ID: 32090344
[TBL] [Abstract] [Full Text] [Related]
13. miRNA-21 promotes cell proliferation and invasion via vhl/PI3K/AKT in papillary thyroid carcinoma.
Zang C; Sun J; Liu W; Chu C; Jiang L; Ge R
Hum Cell; 2019 Oct; 32(4):428-436. PubMed ID: 31161410
[TBL] [Abstract] [Full Text] [Related]
14. Novel therapeutic roles of MC-4 in combination with everolimus against advanced renal cell carcinoma by dual targeting of Akt/pyruvate kinase muscle isozyme M2 and mechanistic target of rapamycin complex 1 pathways.
Son JY; Yoon S; Tae IH; Park YJ; De U; Jeon Y; Park YJ; Rhyu IJ; Lee BM; Chung KH; Lim JE; Lee SJ; Lee HW; Kwak JH; Kim HS; Choi HY
Cancer Med; 2018 Oct; 7(10):5083-5095. PubMed ID: 30160042
[TBL] [Abstract] [Full Text] [Related]
15. The role of TERT promoter mutations in postoperative and preoperative diagnosis and prognosis in thyroid cancer.
Jin A; Xu J; Wang Y
Medicine (Baltimore); 2018 Jul; 97(29):e11548. PubMed ID: 30024548
[TBL] [Abstract] [Full Text] [Related]
16. Clinicopathological features of low-grade malignant endolymphatic sac tumors.
Wang HQ; Jie L; Shi HY
Pathol Res Pract; 2018 Mar; 214(3):431-435. PubMed ID: 29482989
[TBL] [Abstract] [Full Text] [Related]
17. Expression of vhl tumor suppressor mRNA and miR-92a in papillary thyroid carcinoma and their correlation with clinical and pathological parameters.
Todorović L; Stanojević B; Mandušić V; Petrović N; Živaljević V; Paunović I; Diklić A; Saenko V; Yamashita S
Med Oncol; 2018 Jan; 35(2):17. PubMed ID: 29340905
[TBL] [Abstract] [Full Text] [Related]
18. Surgical approaches in hereditary endocrine tumors.
Iacobone M; Citton M; Viel G; Schiavone D; Torresan F
Updates Surg; 2017 Jun; 69(2):181-191. PubMed ID: 28455835
[TBL] [Abstract] [Full Text] [Related]
19. Prognostic significance of diffuse sclerosing variant papillary thyroid carcinoma: a systematic review and meta-analysis.
Vuong HG; Kondo T; Pham TQ; Oishi N; Mochizuki K; Nakazawa T; Hassell L; Katoh R
Eur J Endocrinol; 2017 Apr; 176(4):433-441. PubMed ID: 28183787
[TBL] [Abstract] [Full Text] [Related]
20. Deregulated expression of vhl mRNA variants in papillary thyroid cancer.
Baldini E; Tuccilli C; Arlot-Bonnemains Y; Chesnel F; Sorrenti S; De Vito C; Catania A; D'Armiento E; Antonelli A; Fallahi P; Watutantrige-Fernando S; Tartaglia F; Barollo S; Mian C; Bononi M; Arceri S; Mascagni D; Vergine M; Pironi D; Monti M; Filippini A; Ulisse S
Mol Cell Endocrinol; 2017 Mar; 443():121-127. PubMed ID: 28089820
[TBL] [Abstract] [Full Text] [Related]
[Next]
